| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4df528a427f4bc7e35e5ccd29156f460
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e522ef22f01c13cd40d52aaee98332c4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2fa678f1e18686e6e1c808da98fc0fca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5053f82a7cd17c60822674b657cfb89e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-07 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C213-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C227-34 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C215-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C229-38 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C213-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C59-255
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C229-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C213-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C227-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07B57-00 |
| filingDate |
2001-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2013-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44847692ef286d5fefbd851eb771384e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2964247b8f923b3a36940ba1aa0d6c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5eb5347f8ee3912c49056d1dcfbcd0b7 |
| publicationDate |
2013-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-RE43984-E |
| titleOfInvention |
Process for preparing isomers of salbutamol |
| abstract |
A process for making opticallyOptically pure (R) and (S) salbutamol comprises obtaining the (R) or (S) isomer of either salbutamol or a salbutamol precursor in substantially optically pure formis obtained by resolving a racemic or optically impure mixture of enantiomers of salbutamol or of saida salbutamol precursor with either (L) or (D) tartaric acid, and where necessary converting said isomer of said precursor into either (R) or (S) salbutamol respectively; then optionally converting said optically pure (R) and/or (S) salbutamol into a pharmaceutically acceptable salt. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8765153-B2 |
| priorityDate |
2000-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |